The Unwritten Rules of Effective Biopharma Boards
Governance manuals will teach you about fiduciary duties, committee charters, and board meeting procedures. Law firms will send you onboarding memos about Caremark duties and Revlon obligations. These resources cover the formal architecture of board governance, and they are necessary.
They are also insufficient. The difference between a board that governs effectively and one that goes through the motions has almost nothing to do with the formal governance framework. It has everything to do with the unwritten rules — the norms, expectations, and habits that shape how directors actually interact with each other, with management, and with the decisions that determine whether the company succeeds or fails.
These rules are rarely documented. They are learned through experience, often through the painful process of watching what happens when they are violated. What follows is an attempt to make the implicit explicit.
Never Surprise the CEO in a Board Meeting
This is perhaps the most important unwritten rule in governance, and it is the one most frequently broken by new directors who want to demonstrate their value.
If you have a concern — about the clinical data, about the burn rate, about a management decision — raise it with the CEO before the meeting. Call them. Email them. Ask for fifteen minutes on the phone. Explain your concern and give them the opportunity to address it, to prepare a response, or to adjust their presentation to account for it.
When you blindside the CEO with a tough question in front of the full board, several bad things happen simultaneously. The CEO becomes defensive rather than reflective. The discussion becomes performative rather than substantive. Other directors who might share your concern distance themselves from it because the social dynamics of the room have shifted from governance to confrontation. And the CEO begins to view you as a threat rather than a resource, which destroys your ability to influence their thinking on future issues.
This does not mean you should suppress concerns. It means you should surface them in a way that produces the best outcome. A CEO who has been forewarned about a board member's concern will either resolve it before the meeting — making the discussion unnecessary — or will come prepared to address it thoughtfully. Both outcomes are better than a surprise.
The exception to this rule is when the CEO is the problem. If you believe the CEO is withholding information, misrepresenting the company's position, or acting contrary to the company's interests, you should raise that concern with the board chair or lead independent director, not with the CEO directly. This is a fundamentally different situation that requires a different protocol.
The Pre-Meeting Is Where the Real Work Happens
Formal board meetings are, in many cases, ratification events. The real governance work — the candid discussions, the pressure-testing of assumptions, the alignment of perspectives — happens before the meeting begins.
Effective board chairs understand this. They call directors individually before important meetings to understand their concerns, to identify potential disagreements, and to gauge whether the board is likely to support management's recommendation. They use these conversations to shape the meeting agenda, to ensure that the most important topics receive adequate time, and to surface issues that directors might be reluctant to raise in a group setting.
Directors who participate only in the formal meeting are governing with one hand tied behind their back. If you are not having conversations with the chair, with fellow directors, and occasionally with management between meetings, you are receiving a curated version of reality four times a year and calling it oversight.
This does not mean conducting board business outside the board. Decisions should be made in the formal meeting, with a quorum, and properly documented. But the preparation, the thinking, and the relationship-building that make those decisions sound cannot happen in a three-hour meeting that also includes committee reports and management presentations.
Silence Is Agreement
In many social settings, staying quiet is neutral. In a boardroom, it is not. When a director says nothing during a discussion, the board interprets that silence as agreement. When the vote is taken and it is unanimous, every director — including the ones who said nothing — owns the decision equally.
This is not a cultural norm. It is a legal reality. If the board approves a transaction that later proves problematic, every director who voted for it (or who did not object) shares the governance responsibility. A director who privately disagreed but stayed silent has the worst of both outcomes: the moral discomfort of having supported something they believed was wrong, and the legal exposure of having voted for it.
Effective directors speak up. They do not need to speak at length. A simple "I have a concern about this" or "I think we are moving too fast" or "Can we discuss the alternative before we vote?" is sufficient to ensure that the concern is heard and documented.
If you find yourself consistently staying silent on matters where you have reservations, you need to examine why. Is the board culture discouraging dissent? Are you concerned about social consequences? Do you feel unqualified to weigh in? Each of these is a problem worth solving, because a director who does not speak is a director who is not governing.
Manage Your Relationship with the Lead Investor Carefully
In most venture-backed biopharma companies, the lead investor's representative on the board has disproportionate influence. They may have negotiated the terms that created the company's capital structure. They may have recruited the CEO. They may control enough board votes to block any decision they oppose. They often have the most direct and frequent communication with the CEO.
As an independent director, your relationship with the lead investor's representative is one of the most important dynamics you must manage. Get it wrong, and you become irrelevant — either by becoming a rubber stamp for the investor's preferences, or by becoming so adversarial that you are marginalized.
The right approach is collegial independence. You respect the investor's expertise, their capital commitment, and their role in building the company. You engage constructively with their perspectives. But you maintain your own judgment and are willing to disagree when the company's interests and the investor's interests diverge.
In practice, this means building a direct relationship with the lead investor's representative early — understanding their fund's position, their timeline, and their expectations for the company. Most investor directors will be candid about these things if asked directly. This information helps you understand their perspective and anticipate situations where conflicts may arise.
It also means being willing to be the first person in the room to say "I see this differently." Investor directors are accustomed to controlling the narrative in small boards. An independent director who respectfully but firmly offers a different view changes the dynamic for the better — even if the investor's preferred course ultimately prevails.
Know When to Be Helpful and When to Be Hard
Boards oscillate between two failure modes. Some boards are perpetually supportive — praising management, approving every recommendation, treating the CEO as an ally rather than an employee. Other boards are perpetually skeptical — questioning every decision, demanding excessive documentation, treating the CEO as a subordinate rather than a partner.
The effective board knows when to be which. During periods of normal operations, when the company is executing its development plan and the CEO is delivering on milestones, the board's role is primarily supportive. Ask questions, provide counsel, connect management with relevant contacts, and create an environment where the CEO feels comfortable sharing both good and bad news.
During periods of stress — a clinical setback, a cash crunch, a management failure, an unexpected competitive development — the board's role shifts. The questions become harder. The scrutiny becomes more intense. The expectation of transparency becomes non-negotiable. This is not a betrayal of the supportive relationship. It is the governance function working as designed.
The transition between these modes should be smooth and understood by everyone involved. A CEO who has experienced only a supportive board will be shocked when the board suddenly becomes demanding after a clinical hold. A board that has established the pattern — we are supportive when things are on track, we are rigorous when things go wrong — creates an environment where the shift is expected and not personal.
Never Negotiate Your Compensation in the Room
Independent director compensation — equity grants, board fees, committee compensation — should be established by policy and applied consistently. If you believe the compensation is inadequate, raise it with the board chair or the compensation committee chair privately, outside the meeting.
Negotiating your own compensation in a board meeting, or worse, as a condition of approving a transaction or supporting a management recommendation, is a governance violation that will permanently damage your credibility. It converts your role from fiduciary to participant, and it gives every other director and every officer in the room reason to question whether your judgment on any issue is influenced by self-interest.
If the company's director compensation is genuinely below market, make that case with data. If the board agrees, the change benefits all directors equally. If the board disagrees, accept the decision and decide whether you want to continue serving at the current compensation. This is the only way to handle the issue with integrity.
Protect Executive Session Confidentiality Absolutely
Executive sessions — time when independent directors meet without management present — are essential to effective governance. They provide the only forum where directors can discuss CEO performance, board effectiveness, and governance concerns without the social pressure of the CEO and investor directors in the room.
These sessions work only if their confidentiality is absolute. The moment a director shares what was discussed in executive session with the CEO, with an investor director, or with anyone outside the session, the trust that makes the forum valuable is destroyed. Future sessions become performative because directors know their comments will be reported. The board loses its only space for candid self-assessment.
If the executive session produces a concern that needs to be communicated to the CEO, the board chair or lead independent director should deliver that feedback — as a message from the independent directors as a group, without attributing specific comments to specific directors. This is the appropriate channel. Individual directors freelancing by sharing executive session content with management is a serious governance breach.
Your Preparation Is Visible
Directors often underestimate how obvious it is when they have not prepared for a meeting. The question that was answered on page fourteen of the board pack. The confusion about a milestone that was clearly described in the pre-read materials. The comment that reveals unfamiliarity with the company's current clinical status.
Management notices. Other directors notice. And over time, a pattern of insufficient preparation erodes your influence. When you do raise a substantive concern, it carries less weight because the room has learned that you are not always fully informed.
The standard is high in biopharma because the materials are technical and the stakes are significant. Read everything. If you do not understand something, research it or call the relevant executive for clarification before the meeting. Arrive prepared to engage with the substance of every agenda item.
This is not about impressing people. It is about fulfilling the duty of care, which requires informed decision-making. A director who votes without having read the materials is not meeting the standard, regardless of how the vote turns out.
The Board's Culture Is Set by Its Weakest Norms
Every board develops a culture — a set of shared expectations about how directors behave, how meetings are conducted, and what level of engagement is acceptable. This culture is not set by the most diligent director. It is set by the least diligent behavior that the board tolerates.
If one director consistently arrives late and no one addresses it, tardiness becomes acceptable. If one director never reads the materials and no one notices, preparation becomes optional. If one director dominates every discussion and no one redirects, genuine deliberation becomes impossible.
The board chair bears primary responsibility for maintaining governance culture, but every director has a role. When you see a norm being violated, address it — directly with the individual if appropriate, or with the chair if a broader conversation is needed. Governance culture degrades gradually, and it is far easier to maintain standards than to restore them after they have eroded.
These Rules Cannot Be Legislated
The governance frameworks, committee charters, and board policies that companies adopt are necessary infrastructure. But they are scaffolding, not substance. The substance of effective governance is the behavior of the individuals who sit around the table — their preparation, their candor, their willingness to engage with difficult questions, and their commitment to the company's interests above their own comfort.
These behaviors cannot be mandated by policy. They can only be cultivated by example, reinforced by culture, and maintained by the collective expectation that every director in the room is held to the same standard.
The best biopharma boards are not the ones with the most detailed governance policies. They are the ones where every director understands and adheres to the unwritten rules that make those policies meaningful. The worst boards are the ones where the policies look impressive on paper and the behavior in the room tells a different story.
Choose to be the director who sets the standard, not the one who follows whatever standard has been set.